Header

UZH-Logo

Maintenance Infos

Treatment of myositis with etanercept (Enbrel®), a recombinant human soluble fusion protein of TNF-α type II receptor and IgG1


Sprott, H; Glatzel, M; Michel, B A (2004). Treatment of myositis with etanercept (Enbrel®), a recombinant human soluble fusion protein of TNF-α type II receptor and IgG1. Rheumatology, 43(4):524-526.

Statistics

Citations

Dimensions.ai Metrics
58 citations in Web of Science®
71 citations in Scopus®
Google Scholar™

Altmetrics

Downloads

24 downloads since deposited on 19 Oct 2018
5 downloads since 12 months
Detailed statistics

Additional indexing

Item Type:Journal Article, refereed, original work
Communities & Collections:National licences > 142-005
Dewey Decimal Classification:610 Medicine & health
Scopus Subject Areas:Health Sciences > Rheumatology
Health Sciences > Pharmacology (medical)
Language:English
Date:1 April 2004
Deposited On:19 Oct 2018 07:19
Last Modified:26 Jan 2022 18:01
Publisher:Oxford University Press
ISSN:1462-0324
OA Status:Hybrid
Free access at:Publisher DOI. An embargo period may apply.
Publisher DOI:https://doi.org/10.1093/rheumatology/keh062

Download

Hybrid Open Access

Download PDF  'Treatment of myositis with etanercept (Enbrel®), a recombinant human soluble fusion protein of TNF-α type II receptor and IgG1'.
Preview
Content: Published Version
Language: English
Filetype: PDF (Nationallizenz 142-005)
Size: 145kB
View at publisher